复发性卵巢癌女性对治疗建议的依从性及结局
基于监测、流行病学和最终结果-医疗保险数据库,纳入2369例年龄>65岁、接受手术和铂类化疗后>3个月复发的上皮性卵巢癌女性,按无铂间期(PFI)分为≤6个月、7-12个月和>12个月三组。PFI≤6个月组中66.6%接受非铂治疗,PFI>12个月组中57.6%接受铂类联合治疗;三组中位生存分别为13、18和27个月(P<0.0001)。结论认为PFI是老年复发性卵巢癌女性生存的强预测因子,治疗选择存在广泛差异,许多女性接受非指南方案。
要点
- PFI≤6个月组66.6%接受非铂治疗,PFI>12个月组57.6%接受铂类联合治疗。
- PFI≤6个月、7-12个月和>12个月组中位生存分别为13、18和27个月(P<0.0001)。
- 所有三组中,铂类联合治疗与非铂治疗相比与死亡风险降低相关。
核心结论
- 无铂间期是老年复发性卵巢癌女性生存的强预测因子。
- 复发性卵巢癌女性的治疗选择存在广泛差异,许多女性接受非指南方案。
研究设计与样本
- 使用监测、流行病学和最终结果-医疗保险数据库识别年龄>65岁、接受手术和铂类化疗、辅助治疗完成后>3个月复发的上皮性卵巢癌女性。
- 共识别2369例患者,按无铂间期分为≤6个月、7-12个月和>12个月三组。
- 采用多变量模型分析各组铂类治疗使用的预测因素和生存。
主要发现
- PFI≤6个月组接受铂类联合治疗、单药铂类和非铂治疗的比例分别为28.2%、5.2%和66.6%。
- PFI 7-12个月组接受铂类联合治疗、单药铂类和非铂治疗的比例分别为39.7%、12.4%和47.9%。
- PFI>12个月组接受铂类联合治疗、单药铂类和非铂治疗的比例分别为57.6%、13.2%和29.3%。
- PFI≤6个月、7-12个月和>12个月组的中位生存分别为13、18和27个月(P<0.0001)。
- 所有三组中,铂类联合治疗与非铂治疗相比与死亡风险降低相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Treatment selection for recurrent ovarian cancer is typically based on the duration of time between the completion of adjuvant, platinum-based therapy and the time of recurrence, the platinum free interval (PFI). We examined the use of, and outcomes associated with platinum-based chemotherapy based on the PFI in women with recurrent ovarian cancer. METHODS: The Surveillance, Epidemiology, and End Results-Medicare database was used to identify women aged >65years with epithelial ovarian cancer who underwent surgery and platinum-based chemotherapy and who developed a recurrence >3months after the completion of adjuvant therapy. Patients were stratified by PFI into 3 groups: PFI <6months, PFI 7-12months, and PFI >12months. Multivariable models were used to examine predictors of use of platinum-based therapy and survival for each group. RESULTS: A total of 2369 patients were identified. In women with a PFI of ≤6months, treatment consisted of platinum-based combination therapy in 28.2%, single agent platinum in 5.2% and non-platinum therapy in 66.6%. Corresponding rates of these treatments among women with a PFI of 7-12months were 39.7%, 12.4% and 47.9%, respectively; the rates were 57.6%, 13.2% and 29.3% in those with a PFI of >12months, respectively. Median survival was 13, 18, and 27months for patients with a PFI of ≤6months, 7-12months, and >12months, respectively (P<0.0001). For all three groups, platinum combination therapy was associated with decreased risk of death compared to non‑platinum based therapy. CONCLUSION: Platinum free interval is a strong predictor of survival in elderly women with recurrent ovarian cancer. There is widespread variation in treatment selection for women with recurrent ovarian cancer with many women receiving non-guideline based regimens.
引用
- Champer M, Huang Y, Hou JY, et al. Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence. Gynecol Oncol. 2017. PMID: 29153542. doi:10.1016/j.ygyno.2017.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。